Results 111 to 120 of about 23,985 (238)
Targeting tumor vasculature through oncolytic virotherapy: recent advances [PDF]
, 2015 The oncolytic virotherapy field has made significant advances in the last decade, with a rapidly increasing number of early- and late-stage clinical trials, some of them showing safety and promising therapeutic efficacy.
Merchan, Jaime R +1 more
core +1 more source
Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.Acute myeloid leukemia (AML) is a disease characterized by uncontrolled proliferation and blocked maturation of hematopoietic stem and progenitor cells. Despite progress in its clinical management, many patients continue to relapse or show limited response to standard therapies, emphasizing the need for novel, safe, and more effective targeted ...
Rongrong Hu, Zaker Ataullev, Luping Lou
wiley +1 more source
Turning Cold Tumors Into Hot Tumors: Implications for Cancer Therapy
MedComm, Volume 7, Issue 8, August 2026.Barrier‐defined strategies for cold‐to‐hot tumor conversion. Cold tumors include immune‐desert and immune‐excluded states marked by poor antigen visibility, limited T‐cell priming, stromal or vascular exclusion, metabolic stress and suppressive immune programs.
Xiao Ge +5 more
wiley +1 more source
Engineered Bacterial Membranes as Next‐Generation Platforms for Cancer Immunotherapy
Small Science, Volume 6, Issue 8, August 2026.Engineered bacterial membrane platforms, including outer membrane vesicles, bacterial ghosts, genetically engineered membranes, and hybrid bacterial–tumor membranes, integrate tumor antigen presentation with intrinsic immune stimulation. These platforms promote dendritic‐cell activation, T‐cell priming, pyroptosis, and synergistic responses with ...
Hafiza Aasia Malik +4 more
wiley +1 more source
Potent efficacy signals from systemically administered oncolytic herpes simplex virus (HSV1716) in hepatocellular carcinoma xenograft models [PDF]
, 2014 Lynne Braidwood, Kirsty Learmonth, Alex Graham, Joe Conner Virttu Biologics Ltd, Department of Neurology, Southern General Hospital, Glasgow, UK Abstract: Oncolytic herpes simplex virus (HSV1716), lacking the neurovirulence factor ICP34.5, has highly ...
Braidwood L +3 more
core
Emerging Immune‐Based Therapeutic Strategies in Hepatocellular Carcinoma
Liver International, Volume 46, Issue 8, August 2026.ABSTRACT Hepatocellular carcinoma (HCC) remains a leading cause of cancer‐related mortality worldwide despite recent advances in systemic therapy. The introduction of immune checkpoint inhibitors has substantially expanded treatment options for advanced disease; however, durable responses are observed only in a subset of patients.
Janine Kah +2 more
wiley +1 more source
Development of an oncolytic agent based on the Herpes Simplex Virus type 1 expressing the KillerRed protein targeted to the plasma membrane. [PDF]
openLa viroterapia oncologica rappresenta un promettente approccio per la cura di tumori e neoplasie solide, specialmente per quelli caratterizzati da prognosi infausta e limitata efficacia degli approcci terapeutici classici (resezione chirurgica ...
FEMMINELLA, MADDALENA
core
Oncolytic virus therapy for cancer treatment [PDF]
, 2023 Treballs Finals de Grau de Farmàcia, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, 2023. Tutor/a: Elena Escubedo RafaIn the last few years, oncolytic virus therapy has been increasingly recognised as a new class of ...
Llobet Casajuana, Mireia
core
Bladder Cancer, 2015 Purpose: Despite recent improvements, resistance to traditional immunotherapy or chemotherapy is still common in patients with bladder cancer. We constructed an oncolytic virus from herpes simplex virus type II (HSV-2), which selectively targets tumor ...
Kwan Joong Joo +3 more
doaj +1 more source
Optimization of CEST MRI Reporter Protein Design Using Cation‐Pi Networks
Chemistry – A European Journal, Volume 32, Issue 28, 25 July 2026.A novel engineering approach can produce reporter proteins for cell and viral therapy tracking with unique magnetic resonance imaging (MRI) signatures, detectable with chemical exchange saturation transfer (CEST). We discover how cation‐π interactions between amino acid groups can help us fine‐tune magnetic resonance properties for noninvasive ...
David E. Korenchan +8 more
wiley +1 more source